Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totaling 74,846 shares, a decline of 83.8% from the August 31st total of 461,661 shares. Based on an average daily volume of 184,597 shares, the days-to-cover ratio is currently 0.4 days. Approximately 10.6% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AEMD shares. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $1.50.

Aethlon Medical Trading Down 0.6%

NASDAQ AEMD opened at $6.77 on Friday. Aethlon Medical has a 12 month low of $1.41 and a 12 month high of $41.35. The stock has a market cap of $4.81 million, a PE ratio of -0.19 and a beta of 1.40. The stock’s 50 day moving average is $3.04 and its 200 day moving average is $7.19.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). On average, analysts forecast that Aethlon Medical will post -5.74 EPS for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.